Successful treatment with sorafenib in patients with advanced hepatocellular carcinoma: clinical case

Multi-kinase inhibitor sorafenib is the only one drug which increases life time in patients with advanced hepatocellular carcinoma (HCC). Results from the SHARP trial showed that median progression-free survival was less than 5 months. However, it is possible to achieve strong treatment effect for s...

Popoln opis

Shranjeno v:
Bibliografske podrobnosti
Main Authors: Yu V Bisovskaya, V V Breder, B M Medvedeva, V A Gorbunova
Format: Artigo
Jezik:Russo
Izdano: IP Habib O.N. 2014-06-01
Serija:Современная онкология
Teme:
hepatocellular carcinoma
sorafenib
chronic hepatitis b
lamivudine
Online dostop:https://modernonco.orscience.ru/1815-1434/article/view/26969
Oznake: Označite
Brez oznak, prvi označite!

Podobne knjige/članki